Tengsheng Pharmaceuticals-B (02137) will announce its ongoing ENSURE Phase 2 study data in the form of a latest breakthrough poster at the 2025 EASL Conference.

Wisdom Financial News APP news, Tengsheng Boyao-B (02137) announced that the company presented its ongoing ENSURE Phase 2 study data in the form of a latest breakthrough poster at the 2025 European Association for the Study of the Liver (EASL) Conference held in Amsterdam, Netherlands.